Article: Teva and Aventis Announce That COPAXONE Pre-Filled Syringe is Now Available Also in Europe.

JERUSALEM -- Combined with COPAXONE(R) sustained effect, the pre-filled syringe form significantly improves quality of life for patients with Multiple Sclerosis

Teva Pharmaceutical Industries Ltd. and Aventis Pharma today announced that the Multiple Sclerosis (MS) therapy COPAXONE(R) (glatiramer acetate injection) is now available also in Europe in a pre-filled, ready-to-use syringe (PFS). For physicians, nurses and pharmacists, compliance and adherence to treatment are among the most important factors in any therapy. With COPAXONE(R) PFS, injection will be faster and more convenient. No mixing or preparation is required, and fewer supplies are needed, ensuring ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!